If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Nitrogenous fertilizers tend to create acidic conditions, which are fatal to the worms, and dead specimens are often found on the surface following the application of various pesticides, among which insecticides and fungicides are the most toxic. In Australia, changes in farming practices such as the application of superphosphates on pastures and a switch from pastoral farming to arable farming had a devastating effect on populations of the giant Gippsland earthworm Megascolides australis, leading to their classification as a protected species. Globally, certain earthworm populations have been devastated by deviation from organic production and the spraying of synthetic fertilizers and biocides, with at least three species now listed as extinct, but many more endangered.
== Structure == In humans, the gene for StAR is located on chromosome 8p11.23 and the protein has 285 amino acids. The signal sequence of StAR that targets it to the mitochondria is clipped off in two steps with import into the mitochondria. Phosphorylation at the serine at position 195 increases its activity. The domain of StAR important for promoting cholesterol transfer is the StAR-related transfer domain (START domain). StAR is the prototypic member of the START domain family of proteins and is thus also known as STARD1 for "START domain-containing protein 1". It is hypothesized that the START domain forms a pocket in StAR that binds single cholesterol molecules for delivery to P450scc. The closest homolog to StAR is MLN64 (STARD3). Together they comprise the StarD1/D3 subfamily of START domain-containing proteins.
=== Sarcopenia and sarcopenic obesity === In a recently published scoping review led by Kalra, the current evidence linking sarcopenic obesity with cardiovascular disease has been summarised, along with proposed preventive and therapeutic strategies. He has published extensively to enable the diagnosis of sarcopenia and sarcopenic obesity in resource-constrained settings and has led the development of a South Asian consensus document on the subject.
=== 1880s === 1880: Self-taught German chemist Agnes Pockels began investigating surface tension, becoming a pioneering figure in the field of surface science. The measurement equipment she developed provided the basic foundation for modern quantitative analyses of surface films. 1880: Norwegian zoologist and malacologist Birgitte Esmark's publication on mollusks becomes the first time in Norway that a woman had a scientific work published. 1881: Italian scientists Evangelina Bottero and Carolina Magistrelli became the first women to achieve doctoral degrees in science in unified Italy. 1883: American ethnologist Erminnie A. Smith, the first female field ethnographer, published her collection of Iroquois legends Myths of the Iroquois. 1884: English zoologist Alice Johnson's paper on newt embryos became the first paper authored by a woman to appear in the Proceedings of the Royal Society. 1885: British naturalist Marian Farquharson became the first female Fellow of the Royal Microscopical Society. 1886: American botanist Emily Lovira Gregory became the first female member of the American Society of Naturalists. 1887: Rachel Lloyd became the first American woman to receive a PhD in chemistry, completing her research at the Swiss University of Zurich. 1888: Russian scientist Sofia Kovalevskaya discovered the Kovalevskaya top, one of a brief list of known rigid body motion examples that are tractable by manipulating equations by hand. 1888: Scottish astronomer Williamina Fleming discovered the Horsehead Nebula on a telescope-photogrammetry plate.
=== Shelf life === The shelf life of canned evaporated milk varies according to both its added content and its proportion of fat. For the regular unsweetened product, a shelf life of 15 months may be expected before any noticeable destabilization occurs.
Sources: en.wikipedia.org
Plants that cause illness or death after consuming them are referred to as poisonous plants. The toxins in poisonous plants affect herbivores, and deter them from consuming the plants. Plants cannot move to escape their predators, so they must have other means of protecting themselves from herbivorous animals. Some plants have physical defenses such as thorns, spines and prickles, but by far the most common type of protection is chemical. Over millennia, through the process of natural selection, plants have evolved the means to produce a vast and complicated array of chemical compounds to deter herbivores. Tannin, for example, is a defensive compound that emerged relatively early in the evolutionary history of plants, while more complex molecules such as polyacetylenes are found in younger groups of plants such as the Asterales. Many of the known plant defense compounds primarily defend against consumption by insects, though other animals, including humans, that consume such plants may also experience negative effects, ranging from mild discomfort to death. Many of these poisonous compounds also have important medicinal benefits. The varieties of phytochemical defenses in plants are so numerous that many questions about them remain unanswered, including:
== Regulation and feedback == Several key enzymes can be activated through DNA transcriptional regulation on activation of SREBP (sterol regulatory element-binding protein-1 and -2). This intracellular sensor detects low cholesterol levels and stimulates endogenous production by the HMG-CoA reductase pathway, as well as increasing lipoprotein uptake by up-regulating the LDL-receptor. Regulation of this pathway is also achieved by controlling the rate of translation of the mRNA, degradation of reductase and phosphorylation.
=== Genesis === In March 1988, the U.S. government entered into negotiations with Noriega seeking his resignation. Panama was represented at those negotiations by Rómulo Escobar Bethancourt. Negotiations collapsed after several months of lengthy and inconclusive talks; according to Dinges, Noriega had no intentions of ever resigning. On December 15, 1989, the PRD-dominated legislature spoke of "a state of war" between the United States and Panama. It also declared Noriega "chief executive officer" of the government, formalizing a state of affairs that had existed for six years. The U.S. government stated that Noriega's forces were harassing U.S. troops and civilians. Three incidents in particular occurred very near the time of the invasion, and were mentioned by Bush as a reason for the invasion. In a December 16 incident, four U.S. personnel were stopped at a roadblock outside PDF headquarters in the El Chorrillo neighborhood of Panama City. The United States Department of Defense said that the servicemen were traveling unarmed in a private vehicle, and that they attempted to flee the scene only after their vehicle was surrounded by a crowd of civilians and PDF troops. First Lieutenant Robert Paz of the United States Marine Corps was shot and killed in the incident. An American couple who witnessed the incident was also arrested and harassed by the PDF.
== Testing for HHV-6 == The table below presents a comprehensive overview of various diagnostic tests used to detect human herpesvirus 6 (HHV-6), detailing their ability to distinguish between active and latent infections. It also includes insights on the interpretation of test results, identifies providers that offer these tests, and indicates which methods are suitable for detecting HHV-6A in the endometrial lining—an important consideration for evaluating potential causes of infertility in women. The table serves as a guide for healthcare professionals to select appropriate diagnostic tests for HHV-6.
== Management == Treatment is by medication and/or surgery. Medication consists mainly of acetylcholinesterase inhibitors to directly improve muscle function and immunosuppressant drugs to reduce the autoimmune process. Thymectomy is a surgical method to treat MG especially in younger patients and those with a thymoma.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.